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Abstract
Background: Seroadaptation strategies such as serosorting and seropositioning originated within communities of men who
have sex with men (MSM), but there are limited data about their effectiveness in preventing HIV transmission when utilized
by HIV-negative men.
Methodology/Principal Findings: Data from the EXPLORE cohort of HIV-negative MSM who reported both seroconcordant
and serodiscordant partners were used to evaluate serosorting and seropositioning. The association of serosorting and
seropositioning with HIV seroconversion was evaluated in this cohort of high risk MSM from six U.S. cities. Serosorting was
independently associated with a small decrease in risk of HIV seroconversion (OR=0.88; 95%CI, 0.81–0.95), even among
participants reporting $10 partners. Those who more consistently practiced serosorting were more likely to be white
(p=0.01), have completed college (p=,0.0002) and to have had 10 or more partners in the six months before the baseline
visit (p=0.01) but did not differ in age, reporting HIV-infected partners, or drug use. There was no evidence of a
seroconversion effect with seropositioning (OR 1.02, 95%CI, 0.92–1.14).
Significance: In high risk HIV uninfected MSM who report unprotected anal intercourse with both seroconcordant and
serodiscordant partners, serosorting was associated with a modest decreased risk of HIV infection. To maximize any
potential benefit, it will be important to increase accurate knowledge of HIV status, through increased testing frequency,
improved test technology, and continued development of strategies to increase disclosure.
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Introduction
Over the past decade, reports of increases in unprotected anal
intercourse among men who have sex with men (MSM) in multiple
settings led to concern for subsequently rising rates of HIV and
STDs which have been widely observed[1]. However, at least in a
few areas, available epidemiologic data suggest that HIV incidence
in MSM may not have increased as expected despite a rise in
reported unprotected anal intercourse during the same period[2].
One possible explanation proposed for this discrepancy has
been the observation that some MSM utilize certain HIV risk
reduction strategies that are based on their own HIV infection
status, and that of their partners. Various community-originated
strategies have been reported from multiple areas[3,4,5] and have
been called ‘seroadaptation’ and can include selectively choosing
partners with an identical HIV serostatus to one’s own, or
choosing specific sexual practices based on a partner’s serostatus.
For example, one definition of the seroadaptation practice known
as serosorting is that some MSM who practice anal intercourse use
condoms with partners whose HIV infection status differs from
theirs (serodiscordant partners) but have unprotected anal
intercourse with seroconcordant partners[6]. Additionally, the
terms strategic positioning or seropositioning have been inter-
changeably used to describe unprotected anal intercourse between
HIV serodiscordant MSM, in which the HIV uninfected partner is
preferentially insertive during anal intercourse [7].
However, practicing seroadaptation as a method of HIV
prevention requires decision-making based on often-imperfect
knowledge of HIV serostatus. Interviews with recently HIV
infected gay men have reported failures of seroadaptation[8] and
in a recent cross-sectional study of MSM attending a Seattle STD
clinic, while seroadaptation practices were safer than unprotected
anal intercourse without consideration of partner’s infection status,
they were associated with an increased risk of infection when
compared to consistent condom use[9]. Finally, unprotected anal
intercourse with partners believed to be HIV-uninfected has been
associated with HIV seroconversion in cohort and case control
studies of HIV-negative MSM[10,11,12]. Additional knowledge of
whether and to what extent seroadaptation prevents infection
in HIV-negative MSM is therefore important in determining
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prevention tools for this group.
We evaluated the frequency and predictors of two seroadapta-
tion strategies reported by HIV-negative MSM reporting multiple
partners in the EXPLORE cohort: serosorting (defined in our
study as preferential condom use during anal intercourse with
HIV positive or unknown status partners rather than with HIV
negative partners) and seropositioning (preference for the insertive
rather than receptive role for anal intercourse with HIV positive or
unknown status partners compared to HIV negative partners).
Furthermore, we evaluated the association of these practices with
HIV seroconversion.
Methods
The EXPLORE study was a randomized trial of an individual-
ized behavioral HIV prevention intervention in HIV-negative
MSM in six U.S. cities from 1999–2003. The primary study
outcome, HIV incidence, showed a modest decrease (HR=0.82,
p=0.64–1.05) that did not reach statistical significance[13].
Full methods of the study have been described previously [14].
In brief, subject demographics were assessed at baseline, and risk
behavior was ascertained using audio computer-assisted self-
assessment at 6-month intervals for up to 48 months. HIV
antibody testing was performed by enzyme linked immunosorbent
assay at these semi-annual visits. From the sexual behavior data
collected every six months, we assessed the total number of anal
intercourse acts with HIV infected or unknown serostatus partners
(HIV+/u) and HIV uninfected partners (HIV-), identified as with
or without a condom, then further classified as insertive or
receptive anal intercourse. Serosorting compared the occurrence
of acts with versus without a condom in the HIV+/u compared
to HIV- partners and was restricted to MSM reporting both
serostatus partners and sex with and without a condom. Sero-
positioning compared the occurrence of insertive versus receptive
acts in the HIV+/u versus HIV- partners, and was restricted to
men reporting both serostatus partners and insertive and receptive
sex. In all current analyses, we combined the contacts with HIV
infected and HIV status unknown partners into a single response
category (HIV+/u), both because of the relative infrequency of
anal intercourse with HIV infected partners, and because public
health messages advise that safest sex practices be used equally
with HIV positive and unknown serostatus partners, given the
strong association of unprotected anal intercourse with HIV status
unknown partners with HIV seroconversion[10,11,12].
The baseline demographic characteristics and reported risk
behaviors for the subgroups included in the seropositioning and
serosorting analyses were each compared to the entire EXPLORE
cohort.
For each participant, using all the episodes reported in a time
period, a serosorting score was calculated as the odds of using a
condom with HIV+/u partners, divided by the odds of using a
condom with HIV- partners. Similarly, a seropositioning score was
calculated as the odds of being the insertive partner in anal
intercourse episodes with HIV+/u partners, divided by the odds of
being the insertive partner in episodes with HIV- partners. For
example, for a participant with a serosorting score of three,
the odds of reporting condom use during anal intercourse with
HIV+/u partners was three times higher than in episodes with
their HIV- partners. In contrast, a participant with a seroposition-
ing score of one was equally likely to be insertive during anal
intercourse with HIV+/u and HIV- partners. Isolated zero cell
values were replaced by 0.5 to avoid infinite values of the score;
however, no score was computed if any marginal total of the
two-by-two tabulation of contacts by partner serostatus and
condom use or role was zero – for example, if no contacts with
HIV+/u partners or no unprotected contacts were reported.
To identify correlates of serosorting, we compared the baseline
characteristics of participants with scores four or more to those
with scores of one or less, using t- or chi-square tests as appro-
priate. To a first approximation, these cutoffs result in comparing
the upper and lower tertiles of the scores. For this analysis only,
participant scores were based on anal intercourse contacts aggre-
gated across all study visits.
To assess the associations of seropositioning and serosorting
with HIV seroconversion, we used the same adaptation of the Cox
model previously employed in the primary analyses of this
outcome in EXPLORE[11]. Specifically, HIV seroconversion
was assessed at each follow-up visit and treated as a discrete-time
survival outcome. In these two models, log transformations of the
participant seropositioning scores and serosorting scores were
defined as time-dependent covariates, using only contacts reported
from baseline through the current visit at which HIV seroconver-
sion was being assessed. Log-transformation was used to achieve
linearity and to avoid undue influence of outliers on the right of
the distribution of scores. We adjusted for covariates previously
used in EXPLORE analyses of HIV seroconversion, including
race/ethnicity, numbers of sexual partners, self-report of sexually
transmitted infections, methamphetamine and heavy alcohol use,
depression, and use of drug and alcohol during sex. However, we
did not adjust for more direct measures of sexual risk, in particular
numbers of unprotected anal intercourse contacts by partner
serostatus and role, since we saw these variables as direct
mediators of seropositioning and serosorting.
Because prior EXPLORE analyses have found increased risk of
seroconversion in association with higher numbers of partners
perceived to be HIV-uninfected[11], the model for serosorting was
also run stratified by number of partners. Similarly, the model
effect of seropositioning was assessed within quartiles of reported
condom use. In both these models, a Wald test for effect
modification was performed.
Results
Of the 4295 participants in EXPLORE, 4113 (96%) had at least
one HIV test result during follow-up. Of these, 2623 (64%)
reported anal intercourse with both HIV+/u and HIV- partners
and inconsistent use of condoms and thus were eligible for
inclusion in the serosorting analysis. In the group of men reporting
anal intercourse with both HIV+/u and HIV- partners, 2667
(65%), reported assuming both receptive and insertive roles for
anal intercourse and were included in the analysis of seroposition-
ing. A total of 2345 men were eligible for inclusion in both
analyses. Some EXPLORE participants reported other seroadap-
tation practices outside of those evaluated in our study, and so
were not included in our analyses. For example, 670 (16%)
reported zero sex acts with HIV+/u partners, 740 (18%) reported
no unprotected sex, and 136 (3%) participants reported no anal
intercourse. Table 1 shows the distribution of baseline demo-
graphic and risk behaviors in the complete EXPLORE cohort as
well as the serosorting and seropositioning subcohorts.
Compared to all EXPLORE participants, those in both
subcohorts were slightly younger and more likely to be college
educated and to have reported HIV risk behaviors including drug
use and ten or more partners. There was also weak evidence that
participants in the serosorting subcohort were more likely to be in
a primary relationship, and that those in the seropositioning
subcohort were more likely to be white. Assignment to the
Serosorting and HIV
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subcohorts.
The distribution of the serosorting and seropositioning scores is
shown in Figure 1. Thirty five percent of the serosorting subcohort
and 43% percent of the seropositioning subcohort had scores less
than one. Serosorting was more consistently practiced than
seropositioning: a score of two or higher was seen in 48% of
participants in the serosorting subcohort, but in only 31% of those
in the seropositioning subcohort. A score of four or greater was
seen in 35% and 17% of the serosorting and seropositioning
subcohorts, respectively.
As shown in Table 2, more consistent serosorters (those with a
score of four or higher) were more likely than non-serosorters
(those with a score of one or less) to be white, college-educated,
and to be in a primary relationship. Consistent serosorters were
less likely than non-serosorters to report 10 or more partners at
baseline. There were no differences in EXPLORE study arm, age,
HIV+/u partners, or drug use; although there was a trend toward
decreased amphetamine use in the consistent serosorters, this did
not achieve statistical significance.
Results of the Cox proportional hazard model for the
association of serosorting with HIV seroconversion are shown in
Table 3. There were a total of 259 HIV seroconversions in
EXPLORE, of which 175 (68%) were in the serosorting subgroup.
Serosorting was independently associated with a 12% decreased
risk of HIV seroconversion for each one unit increase in the
natural log serosorting score (OR=0.88; 95%CI, 0.81–0.95). The
protective effect of serosorting did not differ by the number of
reported partners in the stratified analysis, even for those reporting
Table 1. Demographic characteristics and risk behaviors reported at the baseline visit.
EXPLORE
(n=4295) %
Serosorting Cohort
(n=2623) % p-value
{
Seropositioning
Cohort (n=2667) % p-value
{
Arm
Intervention 2144 50 1253 48 0.0005 1288 48 0.01
Age
,30 1727 40 1089 42 0.01 1116 42 0.0001
31–40 1665 39 1019 39 1045 39
.40 903 21 515 20 506 19
Race/ethnicity
White 3112 73 1936 74 0.08 1983 74 0.0011
Black 281 7 161 6 153 6
Hispanic 652 15 385 15 392 15
Other 250 6 141 5 139 5
Education
Completed College 2757 64 1770 68 ,0.0001 1790 67 ,0.0001
In the past 6 months:
10 or more male partners 1812 42 1283 49 ,0.0001 1261 47 ,0.0001
Reported HIV+ Partners 1215 28 809 31 ,0.0001 814 31 ,0.0001
Reported HIV unknown
Partners
3354 78 2189 84 ,0.0001 2204 83 ,0.0001
Any Drug use 2977 69 1905 73 ,0.0001 1938 73 ,0.0001
Amphetamine use 552 13 388 15 ,0.0001 385 14 0.0001
Injection Drug use 439 10 227 9 ,0.0001 239 9 0.0006
Use of Alcohol or Drugs
before sex
3088 72 1972 75 ,0.0001 1994 75 ,0.0001
In primary relationship 2074 48 1295 49 0.08 1318 49 0.06
{Serosorting Cohort compared to the entire EXPLORE Cohort.
{Seropositioning Cohort compared to the entire EXPLORE Cohort.
doi:10.1371/journal.pone.0012662.t001
Figure 1. Distribution of seropositioning and serosorting
scores.
doi:10.1371/journal.pone.0012662.g001
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shown).
In contrast to serosorting, seropositioning was not significantly
associated with HIV seroconversion in the adjusted model
(OR=1.02; 95%CI, 0.92–1.14), as shown in Table 4. In the
analysis stratified by quartile of reported condom use (1–100%) no
effect modification was detected (p=0.63) (data not shown).
Discussion
Approximately 65% of the high risk EXPLORE cohort met our
criteria for inclusion in either subcohort and among these,
serosorting and seropositioning were both reported by a sizable
minority. By definition, the seropositioning and serosorting cohorts
comprise men who report both HIV-uninfected and HIV
positive/unknown anal intercourse partners, as well as inconsistent
condom use and/or role versatility, and are thus behaviorally at
higher risk for HIV. For almost half of the serosorting subcohort,
the odds of using a condom with HIV-infected or unknown status
partners were at least twice that with partners believed to be HIV-
uninfected.
Other studies in HIV-uninfected MSM in multiple areas
including a Seattle STD clinic [9] a cross-sectional survey in
Atlanta [15] and a cohort study in Australia[16] have defined
serosorting as reporting unprotected anal intercourse only with
partners believed to be HIV uninfected and found prevalences of
this strategy of 26–38%. The prevalence of serosorting in our
study is not directly comparable, because we focused on a
subgroup of high-risk men who reported both HIV positive/
unknown and HIV negative partners and both protected and
unprotected anal intercourse. However, this did allow us to
evaluate preferential condom use by partner type within a
participant, which may identify those that intentionally utilized
serososorting as a harm reduction strategy. We found that
seropositioning was reported relatively less commonly than
serosorting in EXPLORE, as was also seen in the Australian
cohort[16]. However, nearly half of the participants in our
analyses did not practice either serosorting or seropositioning, as
shown by scores of #1.
To our knowledge, this is the first evaluation to utilize
multivariable modeling to examine the effect of seroadaptation
strategies on HIV incidence in a large prospective cohort of HIV-
uninfected MSM whose reported behaviors place them among
those at highest risk for HIV infection. Our finding that increasing
serosorting was independently associated with a modest decrease
in risk for HIV infection was encouraging, particularly since this
protective effect was evident even among men with greater
numbers of partners, which has been shown to be a independent
risk factor for HIV infection in EXPLORE as well as another
MSM cohort study[10,11].
Furthermore, in previous studies, both serosorting and strategic
positioning have been associated with an intermediate risk of HIV
seroconversion when compared to no unprotected anal intercourse
(lowest risk) and unprotected receptive anal intercourse with an
HIV-infected partner (highest risk)[9,16]. Certainly, seroconver-
sion has also been reported despite serosorting in case control
studies[12] and surveys of MSM[8]. Modeling studies have also
suggested that attempts at serosorting could paradoxically increase
Table 2. Comparison between serosorters (score.=4) and non-serosorters (score,=1) at baseline visit within the EXPLORE
serosorting subcohort (n=2623).
Non-serosorters (n=926) % Serosorters (n=928) % p-values
Arm 0.85
Intervention 435 47 441 48
Age 0.17
,30 381 41 412 44
31–40 355 38 355 38
.40 190 21 161 17
Race/ethnicity 0.01
White 638 69 701 76
Black 71 8 48 5
Hispanic 162 17 132 14
Other 55 6 47 5
Education
Completed College 572 62 650 70 0.0002
In the past 6 months:
10 or more male partners 465 50 407 44 0.007
Reported HIV+ Partners 273 29 278 30 0.85
Reported HIV unknown Partners 756 82 759 82 0.98
Any Drug use 676 73 669 72 0.70
Amphetamine use 162 17 132 14 0.06
Injection Drug use 83 9 76 8 0.61
Use of Alcohol or Drugs before sex 688 74 703 76 0.5
In primary relationship 417 45 519 56 ,0.0001
doi:10.1371/journal.pone.0012662.t002
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stage of disease which is suspected to be highly infectious due to
high viral loads, but during which conventional HIV antibody tests
are negative[17].
In contrast to our findings, there are several reasons why we
might have expected an increased risk of HIV infection associated
with serosorting or seroadaptation in this study. For one, many
men are unaware of their HIV infection status, and also may make
assumptions about a partner’s HIV status[15,18,19]. Additionally,
as shown in a recent study of over 1800 HIV infected MSM, even
for those who are aware of their own status, disclosure to sex
partners can be complex and fraught with difficulty[20]. It is
possible that the regular frequency of HIV testing, the enhanced
participant-centered counseling that was provided to all EX-
PLORE participants or our inclusion criteria for these analyses
contributed to our findings.
In addition to issues of generalizabilty, the study did have some
additional limitations. Assessments of seropositioning and ser-
osorting relied on participant report, which could have been
subject to desirability bias despite attempts to minimize this by
utilizing computer assisted self-survey. We were also unable to
directly assess participant intention to practice seropositioning
and serosorting as risk reduction strategies, although our study
design did allow for measurement of the magnitude of these
behaviors; neither could we evaluate differences in reported
behavior with regular versus casual partners. Our findings could
be biased by unmeasured confounders, including time-dependent
factors such as knowledge of partner status. In addition our
findings cannot be extended to MSM who are monogamous, do
not practice anal intercourse, or who have only HIV-negative or
HIV positive or unknown status partners. Finally, we measured
only two specific seroadaptation behaviors out of the many
that exist, including some which were reported by EXPLORE
participants, and so cannot speak to the efficacy of those other
practices.
Despite concerns that serosorting may contribute to unaccept-
able risk of HIV infection in MSM[21], our findings were that it
did not increase risk and was even associated with a small
protective effect. However, given this small magnitude of effect,
counseling and health messages should continue to emphasize
condom use and reducing numbers of partners as the mainstays of
individual prevention efforts. Our findings, along with other
studies, suggest that serosorting may have a role as a harm
reduction strategy for MSM who currently practice unprotected
anal intercourse with partners without serosorting. However there
is currently no evidence to suggest that serosorting is as safe as
consistent condom use and limiting numbers of partners.
Further qualitative studies could evaluate intention and skills
associated with MSM who practice these behaviors, and also
whether there are potentially modifiable factors that could be used
to encourage and support serosorting as a harm reduction
approach for MSM who do not always use condoms.
Although using condoms consistently and limiting numbers of
partners remain central to HIV prevention, those MSM who
choose serosorting as harm reduction should also be supported in
this currently practiced, community-originated strategy. First,
since disclosure is the keystone of any seroadaptation strategy,
efforts to decrease barriers and routinize frequent HIV testing
Table 3. Predictors of HIV seroconversion in the EXPLORE serosorting subcohort.
Serosorting Subcohort
n at baseline (n=2623) Adjusted OR 95%CI p-value
Serosorting 0.88 0.81, 0.95 ,0.001
Race/ethnicity
Non-black 2462 Reference
Black 161 1.36 0.76, 2.45 0.30
No. of male sex partners
0–3 484 Reference
4,9 855 1.53 0.92, 2.53 0.10
.=10 1283 2.83 1.80, 4.43 ,0.001
Amphetamines use 388 2.55 1.82, 3.59 ,0.001
Heavy alcohol use 282 1.73 1.05, 2.83 0.03
Self-reported STDs
No STDs 2379 Reference
Gonorrhea 101 2.85 1.60, 5.07 ,0.001
Chlamydia 140 1.76 0.86, 3.58 0.12
Syphilis 3 1.51 0.43,5.31 0.53
Depression scale
7–12 1371 Reference
13–17 875 1.73 1.22, 2.45 0.002
18–22 280 1.27 0.75, 2.14 0.38
23–28 87 2.24 1.21, 4.14 0.01
Use of alcohol or drugs before sex 1972 1.77 1.10, 2.83 0.02
Adjusted for race, number male partners, self-reported gonorrhea, depression, alcohol or drug use before sex, amphetamine use.
doi:10.1371/journal.pone.0012662.t003
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However, since frequent testing alone may be insufficient due to
limitations of antibody testing during acute HIV infection and the
increased risk of HIV transmission associated with this period[22],
improved tests, including pooled RNA testing and more sensitive
fourth generation EIA, should become widely available to improve
diagnostic accuracy of HIV testing for those at high risk of
infection including MSM. Furthermore, additional research into
interventions that encourage and support disclosure to partners is
also necessary to maximize any potential HIV prevention benefit
of serosorting as a harm reduction strategy.
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